Glioblastoma (GBM) is the most common high-grade primary malignant brain tumor with an
extremely poor prognosis. Given the poor survival with currently approved treatments for …

Glioblastoma multiforme (GBM) is a WHO grade IV glioma and the most common malignant,
primary brain tumor with a 5-year survival of 7.2%. Its highly infiltrative nature, genetic …

Gliomas, the most common malignant primary brain tumours, remain universally lethal. Yet,
seminal discoveries in the past 5 years have clarified the anatomy, genetics and function of …

Glioblastoma (GBM) is the deadliest form of brain cancer, with a median survival of less than
2 years despite surgical resection, radiation, and chemotherapy. GBM's rapid progression …

Molecular targeted therapies are revolutionized therapeutics which interfere with specific
molecules to block cancer growth, progression, and metastasis. Many molecular targeted …

Glioblastoma multiforme (GBM) is the most common and aggressive form of primary brain
cancer, for which effective therapies are urgently needed. Chimeric antigen receptor (CAR) …

Glioma is the most common primary cancer of the central nervous system, and around 50%
of patients present with the most aggressive form of the disease, glioblastoma. Conventional …

We conducted a first-in-human study of intravenous delivery of a single dose of autologous T
cells redirected to the epidermal growth factor receptor variant III (EGFRvIII) mutation by a …

Background Rindopepimut (also known as CDX-110), a vaccine targeting the EGFR
deletion mutation EGFRvIII, consists of an EGFRvIII-specific peptide conjugated to keyhole …

The past decade of cancer research has been marked by a growing appreciation of the role
of immunity in cancer. Mutations in the tumour genome can cause tumours to express …